1. Home
  2. MCRB vs BRLS Comparison

MCRB vs BRLS Comparison

Compare MCRB & BRLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • BRLS
  • Stock Information
  • Founded
  • MCRB 2010
  • BRLS 2019
  • Country
  • MCRB United States
  • BRLS Canada
  • Employees
  • MCRB N/A
  • BRLS N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • BRLS
  • Sector
  • MCRB Health Care
  • BRLS
  • Exchange
  • MCRB Nasdaq
  • BRLS NYSE
  • Market Cap
  • MCRB 131.0M
  • BRLS 143.2M
  • IPO Year
  • MCRB 2015
  • BRLS N/A
  • Fundamental
  • Price
  • MCRB $0.73
  • BRLS $6.35
  • Analyst Decision
  • MCRB Buy
  • BRLS
  • Analyst Count
  • MCRB 4
  • BRLS 0
  • Target Price
  • MCRB $5.63
  • BRLS N/A
  • AVG Volume (30 Days)
  • MCRB 2.0M
  • BRLS 6.5K
  • Earning Date
  • MCRB 03-04-2025
  • BRLS 02-12-2025
  • Dividend Yield
  • MCRB N/A
  • BRLS N/A
  • EPS Growth
  • MCRB N/A
  • BRLS N/A
  • EPS
  • MCRB N/A
  • BRLS N/A
  • Revenue
  • MCRB $126,325,000.00
  • BRLS $28,366,370.00
  • Revenue This Year
  • MCRB N/A
  • BRLS N/A
  • Revenue Next Year
  • MCRB N/A
  • BRLS N/A
  • P/E Ratio
  • MCRB N/A
  • BRLS N/A
  • Revenue Growth
  • MCRB 12856.41
  • BRLS N/A
  • 52 Week Low
  • MCRB $0.54
  • BRLS $3.71
  • 52 Week High
  • MCRB $1.53
  • BRLS $12.50
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 37.88
  • BRLS 55.05
  • Support Level
  • MCRB $0.71
  • BRLS $6.03
  • Resistance Level
  • MCRB $0.91
  • BRLS $6.20
  • Average True Range (ATR)
  • MCRB 0.06
  • BRLS 0.50
  • MACD
  • MCRB -0.02
  • BRLS 0.03
  • Stochastic Oscillator
  • MCRB 8.37
  • BRLS 39.62

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About BRLS BOREALIS FOODS INC

Borealis Foods Inc is a food technology company that has developed high-quality, affordable, sustainable, and nutritious ready-to-eat meals. It is a mission-driven company committed to utilizing its products to help solve national and global food security and nutrition challenges. Its commitment to nutrition, affordability, and sustainability reflects its goal of positively impacting both human life and the planet. Through the development and launch of its ready-made ramen, featuring 20 grams of complete plant-based protein per serving, Borealis is developing advanced solutions to address global food challenges.

Share on Social Networks: